NDXP241108P18675000
- 15.96
- 0.000.00%
NASDAQ 100 Index Newsroom
U.S. Stock Market Preview: PPI data higher than expected, s&p 500 futures turn lower; strong performance! Disney pre-market up over 9%, Netease up nearly 5%
Federal Reserve Governor Kugle: Must focus on both inflation and employment targets; Uncertainties increase in the prospect of rate cuts, Federal Reserve officials urge cautious action; taiwan semiconductor rose more than 1% before the market, institutions expect the full load of operation of 3 and 5 nanometers to be maintained in the first half of next year.
Competitor Analysis: Evaluating Amazon.com And Competitors In Broadline Retail Industry
Comparative Study: Meta Platforms And Industry Competitors In Interactive Media & Services Industry
Performance Comparison: Apple And Competitors In Technology Hardware, Storage & Peripherals Industry
Peeling Back The Layers: Exploring Biogen Through Analyst Insights
Evaluating Microsoft Against Peers In Software Industry
Looking Into Alphabet's Recent Short Interest
Here Are the Major Earnings After the Close Today
US Stocks Edge Lower; Cisco Earnings Top Views
What the Options Market Tells Us About Meta Platforms
Reported November 13: Booking.com Now Required to Comply With EU's Digital Markets Act, Allowing Hotels And Travel Providers More Pricing Freedom And Access to Customer Data; Commission Prohibits 'Parity' Clauses, Mandates Compliance Report And...
'Meta Fined $843M By EU Over Marketplace Ads; The Facebook Owner Said It Would Appeal The Fine Imposed By The EU's Antitrust Watchdog' - WSJ
Zscaler Analyst Ratings
Palo Alto Networks Analyst Ratings
Is Super Micro a Big Oversold Buy or Is Relative Strength About to Capitulate Further?
Hims & Hers Health Shares Are Trading Lower in Possible Response to Amazon's Introduction of Its Low Upfront Pricing Telehealth and Medication Plan.
5 Stocks to Watch on Thursday: DIS, AMAT, TPR/CPRI and More
Beyond Meat Expands Beyond Sun Sausage Nationwide At Whole Foods
InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And Β-Thalassemia
Digi Edges Higher Despite Expecting No Revenue Growth in Q1 FY2025